CSCI: cosciensbio.com Expected earnings per share growth for next year

Public company logo of COSCIENS Biopharma Inc. (CSCI)

COSCIENS Biopharma Inc. (CSCI) focuses on therapies for rare endocrine pathologies, utilizing the exclusive diagnostic drug Macrilen to protect its market share. Long-term patents in this niche guarantee consistently high margins due to inelastic patient demand. The business serves as a defensive asset, remaining autonomous from global macroeconomic fluctuations. The company's forward EPS dynamics model demonstrates that the current level is approximately 0.00.

COSCIENS Biopharma Inc (CSCI): Net earnings per share change forecast for next year from 08/10/2024 to 09/14/2025

Analytical breakdowns and data insights for company cosciensbio.com (CSCI)

- share price and consensus valuation forecast:
Stock Price Aeterna Zentaris|CSCI - Broker Consensus Forecast
- market capitalization information:
Market Valuation COSCIENS Biopharma|CSCI - Value Adjusted for Debt and Cash
- book capitalization information:
Net Assets per Single Share COSCIENS Biopharma|CSCI - Net Asset Value|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Capital|Short-Term Debt to Equity COSCIENS Biopharma|CSCI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio COSCIENS Biopharma|CSCI - Company Long-Term Liabilities|Company Short-Term Debts COSCIENS Biopharma|Quick Ratio cosciensbio.com
- net income and valuation ratios data:
CSCI - Net Income|Expected Profit COSCIENS Biopharma Inc.|CSCI - Market Cap to Earnings|Future Price to Earnings COSCIENS Biopharma Inc.|CSCI - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple COSCIENS Biopharma|CSCI - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) COSCIENS Biopharma|CSCI - Net earnings per share for the last four quarters|Quarterly EPS earnings growth cosciensbio.com|CSCI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year COSCIENS Biopharma Inc.
Fundamental company valuation:CSCI, Aeterna Zentaris
Finished products of COSCIENS Biopharma

COSCIENS Biopharma Inc. (CSCI) specialization in patent-protected orphan drugs minimizes price competition, creating a foundation for stable revenue scaling. By analyzing the one-year forward EPS growth rate, an investor assesses the consensus forecast for earnings per share changes, which allows for the mathematical verification of market expectations and the determination of business value potential relative to future financial results.

Analysis of competing companies

VRTX (Vertex Pharmaceuticals Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year ALNY (Alnylam Corp)|Expected earnings per share growth for next year INSM (Insmed Incorporated)|UTHR (unither.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year BioMarin BMRN|BBIO (BridgeBio Pharma) - Net earnings per share change forecast for next year|BGM Group Corp - Earnings growth forecast for next year|Expected earnings per share trend next year COGT (Cogent Corp)|XERS: Earnings growth forecast for next year|kerostx.com (KROS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Arcturus Therapeutics Holdings Inc.|ETON: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Kamada Corp (KMDA)|Expected earnings per share growth for next year Fulcrum Corp FULC|Earnings growth forecast for next year ABEO (Abeona Therapeutics Inc.)|Earnings growth forecast for next year Mereo BioPharma Group MREO|Protalix BioTherapeutics, Inc. - Earnings growth forecast for next year|Pliant Therapeutics (PLRX) - Expected earnings per share growth for next year|Applied Therapeutics, Inc. (APLT) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Aileron Therapeutics (RNTX)|Net earnings per share growth forecast for next year Gelteq Ltd|Aytu Therapeutics (AYTU) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year CMMB|Expected earnings per share growth for next year srxhealth.com SRXH|Earnings growth forecast for next year PLRZ (Polyrizon)|Consensus forecast of earnings per share growth for next year Aeterna Zentaris Inc (AEZS)|Cyclo Therapeutics - Earnings growth forecast for next year|Expected net earnings per share growth next year Inozyme Pharma, Inc.|Reneo Pharmaceuticals, Inc. (RPHM) - Net earnings per share growth forecast for next year